Nufarm Limited (NUF) Earnings Call Transcript & Summary

September 23, 2020

Australian Securities Exchange AU Materials Chemicals earnings 81 min

Earnings Call Speaker Segments

Operator

operator
#1

Good day, everyone, and thank you for joining us on the Nufarm Annual Results Conference Call. <<operator_script>> I want to let you know that this call is being recorded today. At this point, I'll turn things over to today's speaker, Mr. Greg Hunt. Thanks, and please go ahead.

Gregory Hunt

executive
#2

Thanks, Kevin. Morning, everyone. Welcome, and I appreciate you being with us today. This marks the second results release since the tragedy and, I suppose, the COVID disruption started. It's difficult to accept that 6 months have already gone by, and I truly hope all of you are well and, like us, managing the everyday upheaval in your lives. Before we begin today's presentation, I'd like to point you toward the disclaimer, especially the forward-looking statements section. Today, we want to address 3 topics that are essential to Nufarm's value and to our path toward better returns. First, Paul Binfield and I will give an overview of the 2020 financial performance and the actions we've taken to refocus the portfolio, strengthen the balance sheet and generate value from our operations. Our Regional General Manager for Europe, Hildo Brilleman, is with us, and he'll walk us through the European results for financial year '20, but importantly, the performance improvement program that he is leading for the European region. And Brent Zacharias, whom many of you would know, is our group executive for Nuseed, and he'll give an update on the transformational growth opportunities within our seeds portfolio.

Gregory Hunt

executive
#3

Then we'll wrap up by covering the 2021 outlook and priorities, and after that we'll take whatever questions you might have. Before getting into the results, I'd like to begin with how we performed on safety and offer a few remarks about how COVID has affected Nufarm. Nothing matters more to us than safety, and it's a pleasure to report that in 2020 Nufarm delivered the strongest safety results in its history. That didn't happen through chance or luck. Achieving better safety outcomes requires the whole organization pulling together and staying focused. What we face now is the task of cementing those gains and keeping up the vigilance that ensures every employee keeps safety front of mind — and that will remain our #1 priority. We delivered that record safety performance against the backdrop of a global pandemic. As for COVID, we count ourselves very lucky that governments in the markets where we operate deem agriculture an essential industry. Products for crop protection are a vital input to the food value chain, and demand for what we sell has kept being driven mainly by seasonal conditions. For Nufarm, the effects of COVID-19 have largely been confined to the turf and ornamental market in North America along with the horticulture and ornamental markets in Europe.

Gregory Hunt

executive
#4

Our manufacturing and supply chain teams have accomplished a tremendous amount in continuing to serve customers around the world. Every one of our manufacturing sites has stayed open. And while raw material supply has seen some interruptions and logistics have faced some delays, COVID-19 has caused no material financial impact from supply chains. The additional costs we incurred in manufacturing and logistics to keep supply going and to ensure our people's safety have largely been offset by cuts in discretionary spending, and the big hit to our financial performance comes from foreign exchange losses, which Paul will address later. Moving to commercial performance. 2020 was certainly not the year anyone would have planned. While we have been relatively resilient in the face of the pandemic, headwinds from droughts and floods and industry-wide supply chain issues hurt performance, particularly in the first half. We reported a loss of $456 million for the year, which includes $389 million of material items post tax, including the impact of the sale of the South American business and the impairment to the European assets that we announced earlier this month. Looking at the underlying performance of our continuing businesses, EBITDA fell 21% to $236 million, and this was primarily driven by a decline in European earnings and reduced earnings in North America in the first half as it recovered from last year's floods.

Gregory Hunt

executive
#5

While that result is disappointing, momentum improved in the second half, and I'll say more about that shortly. A major focus for us is generating more cash, and we made solid progress there. Underlying cash from operating activities rose $137 million versus the prior year, as better working capital control more than offset lower earnings. Selling our South American business in April of 2020 marked a very significant milestone. It gave shareholders upfront value and has reshaped our portfolio. Our continuing businesses are now concentrated in the regions and businesses where we think we can drive higher margins and better cash flow. That divestment also transformed our balance sheet. Net debt has come down by over $800 million, and leverage has fallen from 3x to 1.9x, or 1.5x excluding the AASB 16 adjustment. That gives us the financial strength to handle the inherent volatility in our industry. Operationally, our Australian, North American and Asian businesses returned to growth in the second half of the year. Our major focus now is driving value from the investments we've made in Europe. We've had another difficult year in that region, with very poor seasonal conditions and elevated raw material costs weighing on margins.

Gregory Hunt

executive
#6

Even so, we think Europe's earnings have bottomed out, and we're capable of producing a substantial improvement in results over the next year. The improvement program we started in Australia in 2019 has now been extended across Europe and the remainder of the company. Our target from this program is $35 million to $40 million in benefits across the next 2 years. A little under half of that should stem from the manufacturing footprint changes we have already announced. The remainder is made up of an extra $10 million to $15 million we are targeting in Europe. Plus a combined $10 million from our corporate and North American operations. The program began earlier this year, and the adjustments we have made to our functional structures and our discretionary costs have delivered a run rate benefit of roughly $5 million as we enter the -- '21 financial year in Europe, along with another $5 million in corporate and North America. We also achieved excellent progress in our Nuseed business. The first commercial sales of omega-3 canola oil took place in September this year. That is a highly significant milestone and signals a move into the next phase of commercial development as we ramp up production and sales.

Gregory Hunt

executive
#7

Nuseed likewise picked up a new technology platform, carinata, over the course of the year, and Brent will address that later on in his presentation. I noted before the positive earnings momentum during the second half, and you can see that here on Slide 7, which displays the improvement region by region and also shows how resilient the business has been to COVID-19 across the last 6 months. In Australia, drought-breaking rains along the East Coast in late January plus good follow-up rain drove strong demand in the second half, and we delivered underlying EBITDA growth of 125% versus the prior year. Our Asian business similarly bounced back from poor seasonal conditions in the first half and added to second half growth as well. In North America, a return to more normal seasonal conditions lifted crop plantings in the second half, which generated higher demand and more than offset the hit from lower demand in the turf and ornamental segment caused by COVID-19 restrictions. EBITDA for the European business fell significantly in the second half, with very weak demand in the final quarter. Higher raw material costs in this business have continued to affect us. Still, one pleasing aspect of the second half result was a reduction in the SG&A cost that we can control.

Gregory Hunt

executive
#8

Hildo will go into more detail on that during his presentation as well. For the Seed Technologies segment, the second half was mixed. Sales rose thanks to higher Nuseed volumes. Earnings, though, fell, because of a bad debt as well as higher commercialization costs for omega-3 and carinata, and Brent will address that shortly. Before handing things over to Paul for the financial details, I'd like to use this moment to note that, after 9 years as CFO of Nufarm, Paul has let us know he'll be departing to pursue new opportunities. He isn't making a quick exit just yet, since he has one more set of accounts to prepare for our next financial year, which wraps up in roughly a week's time. And he will remain with us past that point, through the end of the calendar year. Still, I want to pause and recognize Paul's contribution to Nufarm. Throughout a period of considerable change, he has been a core member of our leadership team. In numerous projects and events that have shaped — and keep shaping — our company, he has played a pivotal role. Paul has carried an enormous workload with skill, agility and always a touch of good humor.

Gregory Hunt

executive
#9

He truly represents what Nufarm stands for, and he played a key role in shaping our culture. He has also been both a colleague and a friend, and we will miss him. I know all of you join me in wishing Paul the very best in his future. Paul?

Paul Binfield

executive
#10

Thanks, Greg. These financial statements are complicated because of the divestment of the South American businesses, and because FY '20 is the first full year in which we adopted the new lease accounting standard AASB 16. Our content today centers on the continuing business, and wherever it is material we will point out how the new leasing standard affects things. I should also flag that, under a transitional supply agreement in Latin America, we made sales to Sumitomo of roughly $85 million at 0 margin. Where appropriate, we have excluded these sales — excluded their impact — from our commentary and from our figures. Since our year end changed to September 30, we have also included information in the appendices of the presentation that restates prior year figures to reflect the 30 September period. As Greg outlined, FY '20 was a disappointing year in terms of our results. We finish this financial year in far better shape than we were in when it began. The balance sheet is much stronger, thanks to the proceeds from the sale of the South American businesses. In addition, better cash flow from improvements in working capital management has also strengthened the balance sheet.

Paul Binfield

executive
#11

For most regions, second-half business momentum was solid, and that has carried through past year-end. Early gains from the performance improvement program are already becoming visible, and we keep hitting the crucial omega-3 milestones. Revenue fell 0.5% in constant currency and excluding the 0 margin sales for Sumitomo, which mirrors a soft first half in Australia and North America plus trading — digital trading conditions in Europe. Underlying EBITDA came to $236 million. Gross profit percentage declined roughly 130 basis points, which mirrors margin pressure in North America and, in particular, Europe. Hildo will walk you through what drove that later in the presentation. Expenses took a hit from the weak Australian dollar. They stayed largely well controlled in North America, ANZ and Asia. In Seed Technologies, expenses ran higher as we built capability to fully commercialize omega-3 and took on board carinata for the last 8 months of the year. European cost increases include a full year of additional supply chain costs incurred in transitioning the acquired portfolios. Depreciation and amortization rose from $165 million in the prior year to $201 million in FY '20, largely the impact of the AASB 16 adjustment, recognizing additional depreciation on right-of-use assets of $24 million.

Paul Binfield

executive
#12

That balance is tied to amortization for products we've launched recently. Financing costs — which take in net external financing, net gains and losses on foreign exchange, and lease amortization — went up by $32 million. Net external financing costs fell by $2 million, landing at $65 million. Foreign exchange losses rose $28 million, ending the year at a loss of $24 million, mainly because of exchange rate volatility linked to the pandemic, especially during that March and April stretch. Finance charges on leases climbed $6 million following adoption of AASB 16. Tax expense took a hit from not recognizing tax benefits on trading losses. Those tax losses can still be used in future periods; they just aren't recognized on the balance sheet. And the dividend stays suspended. Now, looking specifically at material items: material items came to $389 million post tax. We recorded a noncash impairment of intangible assets in the European business of $180 million after tax, reflecting a moderated outlook for future earnings, driven largely by an expectation that margin pressure from the base product portfolio will continue. The profit on disposal of the South American businesses, net of tax expenses and transaction costs, produced a net after-tax loss of $116 million. Partly offsetting that is recognition of a tax asset in Brazil of $9 million in January 2020.

Paul Binfield

executive
#13

We recorded a charge for costs tied to rationalizing assets — specifically the previously announced shutdown of manufacturing plants in Australia and Austria, roughly $20 million apiece — with the remainder consisting of restructuring expenses connected to rolling out a broad performance improvement initiative. Net tax assets totaling $33 million are being written off and recorded as a material item. Although FY '20 proved a highly difficult year for Nufarm, two notable bright spots emerged during it: better cash flow generation, which helped bring about a stronger balance sheet. Nufarm competes in an industry that is intensive when it comes to working capital, so managing net working capital actively and effectively matters greatly if we are to produce acceptable returns for shareholders. The extraordinary weather occurrences in Australia and the U.S. across the past couple of years have added more strain to how we handle our working capital management processes. Even so, during the second half of FY '20 we witnessed highly encouraging indications that our emphasis on working capital management processes is beginning to pay off. Net working capital stood at $143 million below the prior year on 31 July, the low point in our cycle. And average net working capital over sales came in at 46%, moving in the direction of our target range of 35% to 40%.

Paul Binfield

executive
#14

If we land at the very top of the range we've set, that still means more than $150 million of additional cash comes off the balance sheet. Better management of net working capital has carried through into stronger cash flow from underlying operating cash flows, which is $137 million better than the prior year. Capital expenditure was also handled well during the period, and underlying cash flows and net investing activities are $5 million lower than the prior year. The biggest investment in FY '20 was the bulk of the outlay on our new Greenville plant, which we commissioned in September 2019. For FY '21, we anticipate capital expenditure of roughly $180 million. Among the main new projects for the year ahead is a modest amount of CapEx at our Wyke plants in the U.K., aimed at expanding and further fortifying our position in the important profitable phenoxy herbicides that are developed and manufactured there. We will also spend more on development of our omega-3 canola oil as we prepare the product to enter segments beyond agriculture. So, moving to the balance sheet. Our financial position has been considerably strengthened after the divestment of the South American businesses. The net proceeds from that sale went toward reducing debt.

Paul Binfield

executive
#15

At year-end, leverage stood at 1.9x, which sits inside our target range of 1.5 to 2x for core net debt to EBITDA. Core net debt is defined by us as net debt at the working capital cycle's trough — normally reached in July or August — and it also incorporates an AASB 16 adjustment for lease liabilities. Having this target range lets us handle the inherent volatility in our industry more effectively. Strong liquidity is another highlight: undrawn facilities came to $648 million at year-end, and there is additional room to draw further on working capital facilities. Cash held on the balance sheet was $687 million. That puts the business in a very strong position as we move ahead. I'll return the call to Greg, who will give you more detail on how the regions performed.

Gregory Hunt

executive
#16

Yes. Thanks, Paul. So, as I mentioned before, I felt really good about the positive momentum we built in most regions during the second half as headwinds let up. And Australia is probably the clearest illustration of that — it genuinely was a tale of 2 halves. Calendar year 2019 was the hottest and driest ever recorded in Australia, and sales going into the 2020 summer season were extremely weak. Then in late January we got drought-breaking rains, and that drove very strong demand on the East Coast, so our manufacturing plants essentially went from sitting idle to running at full capacity. That gave real momentum to second half earnings, with underlying EBITDA, as I said before, up 125% versus the prior year. On top of that, we estimate roughly $10 million of the full year earnings improvement came from the performance improvement program we launched last year. Through a combination of SG&A and supply chain improvements, that program has taken cost out of our base, and it genuinely leaves us in a more competitive position. The next phase for the Australian business will be closing the insecticide and fungicide manufacturing facility we have in Laverton. That should deliver supply chain benefits of about $5 million per annum starting from the end of calendar year 2021.

Gregory Hunt

executive
#17

We likewise secured a highly meaningful decrease in working capital thanks to robust demand, and we intend to hold on to those gains. Regarding weather, initial signals point to a better outlook for the 2021 summer season. Even so, it remains early days. And we are -- yet even so, our position is far stronger than it was at this same point a year ago. Several product launches slated for financial year '21 will provide additional support for earnings growth. Among these launches are a new insecticide and a new preplant herbicide showing promising activity against mounting ryegrass resistance, which is a genuine problem here in Australia. Moving to Asia, which delivered another very good year notwithstanding the Indonesian drought's impact during the first half. EBITDA has risen 13% versus the prior year, fueled by stronger margins stemming from a shift in geographic and product mix plus ongoing cost control. Asia has contributed steadily to earnings over a long period now. And starting the 1st of October, we will merge it with our Australia and New Zealand business to form a new Asia Pacific region. Through merging these businesses, we can pursue additional efficiencies across our manufacturing and supply chain assets and open up chances to leverage our portfolio more effectively.

Gregory Hunt

executive
#18

In North America, the first half proved tough for us. Even so, we recovered part of that shortfall during the second half thanks to stronger sales into the crop segment, especially in Canada, which more than made up for COVID-19's effect on the turf and ornamentals segment. Underlying momentum in this business is positive. Financial year '21 will give us a full year of benefit from our Greenville facility. It was commissioned last September, and it delivers logistics advantages and lets us react faster to surge demand. That investment also builds on what we put into the new insecticide and fungicide facility in Alsip, along with the significant upgrades at Chicago Heights completed in recent years. Today we have a streamlined, modern and efficient manufacturing footprint in North America for serving our customers. Also, our portfolio is expanded for financial year '21, with several product launches in the U.S. and Canada that build on the new gold distribution agreement, which likewise begins in financial year '21. Now to Europe. The past couple of years have brought challenges. Still, this is a valuable business with a quality portfolio, and we anticipate a strong earnings rebound once headwinds ease and we reinforce our supply chain and lower our cost base.

Gregory Hunt

executive
#19

Now I'll pass things over to Hildo Brilleman. Hildo came to Nufarm in October of last year, and on the 1st of January this year he was appointed to the Regional General Manager position. Hildo brings over 20 years of industry experience, and with a fresh perspective and new energy he is applying that experience to our European business. He'll walk you through what he thinks about Nufarm's business in Europe and how we expect the earnings rebound to unfold. Hildo, over to you.

Hildo Brilleman

executive
#20

Thank you, Greg, and I appreciate the introduction. I also want to thank everyone who has joined us on the call today. I'd like to begin by offering a few of my initial impressions since coming on board at Nufarm, along with the road map we have for the European business. As was mentioned, Nufarm possesses a robust and valuable operation in Europe, supported by a well-established customer base. That operation was constructed around a solid portfolio of phenoxy, PGR, plant growth regulators, and copper fungicide. This is traditional chemistry, yet demand for it remains strong. In every one of these market segments, Nufarm holds a double-digit market share. The acquisitions made in 2018 broadened and diversified our portfolio, and the majority of earnings during the current year were in fact produced by these portfolios. These are good products — strong products that customers want to purchase. They align well with the crops Nufarm is targeting in Europe. I mentioned cereals, oilseed rape pastures, and also the combination of trees, nuts, vines and vegetables, which we refer to as the TNVV crops. The registrations are likewise weighted toward the countries where Nufarm has a strong presence. Germany, France, Spain, the U.K. and Poland. Considerable investment has also gone into people, processes and systems, with a new pan-European ERP system connecting the entire European business for the first time.

Hildo Brilleman

executive
#21

So we’ve got a solid foundation already, and the next items on the European road map involve boosting how competitive our supply chain is along with our cost base. That work is currently in progress. Before walking through the road map in detail, I’d like to discuss what drove the fiscal year ’20 results. To give some context for that, I’ve put in a map illustrating seasonal conditions during the main growing season across Europe in 2020. I’m certain you’re familiar with this type of drought map, since it looks fairly similar to ones you’ve seen for Australia. Still, I must say that following 20 years in this industry, this ranks among the harder years I’ve experienced. Hot, dry weather across Northern and Eastern Europe, extending through Romania and Ukraine, cut demand for crop protection and reduced Nufarm’s revenue in 2020. Sales declined by roughly 3% in Australian dollar terms and by more in constant currency. Rivals have felt this pressure too, which has produced a highly competitive market environment once again this year. From Nufarm’s standpoint, the countries most affected were the U.K., Germany and France.

Hildo Brilleman

executive
#22

We've actually held up pretty well in other markets given the circumstances, and that includes what COVID-19 has done, particularly to horticulture and ornamental markets. If you look at the results on Slide 20, you'll see that the revenue decline came in the second half. The fourth quarter especially was much weaker, because we pulled back on our autumn sales campaign. Two things drove that: channel partners were cautious about building stocks, and we also made a decision on our side to hold back sales so we could optimize margins. That's a change from how we approached things in prior years. Our aim is to optimize margins and get Nufarm inventory in the channel to an appropriate level, so that we can keep stimulating sales closer to end-user demand. On the following slide, I've laid out an overview of the different drivers behind the result. Starting with the biggest movement, volume and mix — that's largely down to the seasonal conditions we just talked about and the shift in sales for the autumn campaign. COVID-19 played a part as well, and we'd expect most of that demand to return once conditions get back to something more normal. I think it's important for me to emphasize here that I'm confident we haven't lost market share in our key markets.

Hildo Brilleman

executive
#23

Second quarter industry black box data confirms this. When we look at the AUD 14 million price driver, that partly mirrors competitive conditions stemming from weaker demand. But there is also a component reflecting pricing pressure coming from generic products, and so we think part of that component is more systemic in nature. And that pricing pressure within our base portfolio was the catalyst for the impairment we took on certain intangible assets. Paul will comment on that later. Turning to cost of goods sold, sustained higher raw material prices had an impact of roughly $12 million, plus another $5 million tied to increased conversion cost at our manufacturing facilities. I'll speak to those factors later, since we do see some easing over the coming 12 to 18 months. SG&A costs also rose, and that figure included some one-off costs as well as a full year of supply costs to transition the acquired portfolios. On the positive side of the ledger, we grew sales of products from our manufacturing plants to other industry participants, and we also expanded sales into nonagricultural markets. In total, it's a disappointing result. However, we believe fiscal year '20 is the earnings trough.

Hildo Brilleman

executive
#24

We have a well-defined strategy to tackle the problems we can influence, and we're already seeing a few early signals that the fiscal year '20 headwinds could be letting up. Now, if you turn to Slide 22, we'll look at the fiscal year '21 outlook and why we're confident this improvement will materialize. Let me begin with the 2 columns on the left-hand side, the ones within our control, which tie back to the road map I mentioned earlier. First, establishing an efficient cost base. Our European business has been through a major transition over the past few years, and in my view, that has led to an inefficient cost base along with one-off costs. Acquiring the portfolios nearly doubled the European business's size. While those portfolios were being integrated, we also brought in a new ERP system, a new shared services center, and new ways of working. That period of upheaval has now ended. We have a clear opportunity ahead to shape the organization so it sits close to our customers, and is agile and efficient. There's also considerable room to lower our cost base as we work through this process. The improvement program in Europe began at the start of this calendar year, when I came in as the Regional General Manager.

Hildo Brilleman

executive
#25

I do need to recognize that the arrival of COVID-19 set us back to some degree, and resources had to be shifted toward handling the early stages of the pandemic, yet despite that we've still achieved solid progress. So far, the effort has concentrated mainly on our back office, with a smaller portion aimed at our supply chain. Over 20 colleagues have departed the company up to now, and additional reductions have been made in discretionary spending, which brings the run rate benefits achieved thus far to roughly $5 million. Plenty of further opportunities remain for us to tackle, and the program's upcoming phase will reach more deeply into supply chain improvement as well as logistics optimization. As I mentioned, our goal is $15 million to $20 million in run rate savings by the close of fiscal year '22, and in my view that goal is realistic. The program's next element concerns making our supply chain more competitive and lowering conversion costs. Earlier this year we carried out a review of our manufacturing footprint. What that analysis revealed is that although our MCPA synthesis and herbicide formulation operations stay competitive, gaps have appeared in the competitive standing of our 2, 4-D synthesis and insecticide and fungicide formulation.

Hildo Brilleman

executive
#26

We've already made it public that our 2,4-D synthesis site in Linz is going to shut down early in the coming calendar year. That lets us source products at a much more competitive cost than what our own operations can achieve. It also lets us sharpen our market offer and lift margins on this key molecule. The projected yearly run rate benefit from this move comes to as much as $10 million. We're still evaluating options for other parts of our manufacturing footprint, and this analysis could open up additional chances to boost margins. Raw material costs make up the third pillar. For a while now, we've held the view that raw material costs would come down as more environmentally compliant capacity comes online in China. But the devastating explosion in Jiangsu province in March last year pushed that back. With the Chinese economy having reopened following the COVID-19 lockdown earlier this year, we're at last seeing better product supply and lower pricing, which indicates that this capacity is at last making its way to the market. And as you can see from these price charts for the active ingredients in tebuconazole and prochloraz, pricing on those products has improved considerably since March.

Hildo Brilleman

executive
#27

Saying the headwinds are behind us is very early. And naturally, before we'd see any benefit, we first have to use up any higher cost inventory we're holding. But if this is a shift that's seen consistently across a broad range of our active ingredients, it does have the potential to improve margins significantly. And weather is the final element among the drivers for fiscal year '21. Obviously, this one is outside our control. However, I think the bridge we provided earlier shows the significant impact this could have on our performance. My colleague in Australia, Peter O'Keeffe, I know had a very difficult 2 years and is now starting to see some of the benefits from the swinging conditions. And I can reassure you the team in Europe is looking forward to also enjoying that. So at this point, I'm going to hand over to Brent Zacharias, who will take you through the Seed Technologies segment. And -- but I'm staying on the call for the Q&A, and I will be very pleased to take any of your questions. Thank you. Brent?

Brent Zacharias

executive
#28

Thanks, Hildo. During FY '20, Nuseed hit several key milestones, especially with regard to our omega-3 canola and carinata platforms. Results for the Seed Technologies segment cover both the Nuseed business and the seed treatment business. Even with considerable headwinds — notably drought effects in Australia — segment revenues rose 8% to $198.8 million. Gross margin also came in higher, driven by greater sales of recently launched products within the seeds portfolios. Although revenues and margin improved, lower endpoint royalty payments on 2019 canola crops in Australia, combined with larger investments in our growth platforms and a one-off bad debt write-down, pushed EBITDA and EBIT performance lower. EBITDA for the segment came to $31.5 million, versus $38.5 million in financial year '19. Moving to the next slide. We're delighted that Nuseed delivered sales growth across every region and all of its core crops. Although canola contributions overall in Australia declined, a substantial shift toward Nuseed hybrids will produce strong royalties coming due in this new financial year. In Latin America, the period brought higher sales of sunflower, canola and sorghum, with Nuseed now standing as the top sorghum supplier in Brazil.

Brent Zacharias

executive
#29

After the new product launches, Nuseed also increased both market share and margins in North America's sorghum market, and it raised volumes and share in the sunflower segment. Importantly, the first sales of Nuseed's hybrid canola were secured in the large Canadian market and in the United States. New products were also successfully launched from Nuseed's strong European sunflower pipeline, helping drive volume and share growth in that region. Moving to the next slide. I'm excited to share some updates of our Omega-3 program to date. Our Value Beyond Yield strategy focuses on building proprietary positions to deliver downstream benefits to customers and consumers. During financial year 2020, we made significant progress on key strategic objectives. In relation to our omega-3 canola platform, we collaborated with key aquaculture industry partners to complete commercial scale fish feeding trials involving more than 1.5 million salmon. These trials demonstrated key benefits of Nuseed's Aquaterra, omega-3 oil, including improved fish health, resulting in improved survivability and improved sustainability outcomes. Our initial commercial 2019 crop was successfully harvested and processed. Just prior to year-end, Health Canada and the Canadian Food Inspection Agency confirmed regulatory approvals for Nuseed omega-3 canola in relation to cultivation, use in aquafeed and livestock feed and for human consumption.

Brent Zacharias

executive
#30

Canada happens to be the biggest canola producer globally and a significant salmon producer as well. In September 2020, we completed the initial commercial sales and forward orders for Aquaterra, our proprietary omega-3 canola oil. This comes after over a decade of development and substantial -- and it marks the start of a new phase in delivering shareholder value from Nuseed's Value Beyond Yield growth platform. We're extremely pleased to have a wide range of leading global aquaculture companies involved in commercial discussions and acknowledging the advantages of Aquaterra when it comes to survivability and sustainability. Efforts to scale production and grow omega-3 canola sales are moving forward now. The 2020 crop is largely harvested and remains on schedule to double oil production for 2021 sales. Canadian regulatory approvals obtained in July 2020 represent a key factor underpinning our upcoming expansion. Marketed under the brand Nutriterra, omega-3 canola is additionally being advanced for the human nutrition sector and finished the patient testing stage of a significant human clinical trial over the year. This marks the first human clinical trial carried out to evaluate safety and efficacy parameters tied to a plant-based omega-3 source. The trial's analysis phase is currently in progress.

Brent Zacharias

executive
#31

Now, on carinata. Last November, Nuseed obtained a second Value Beyond Yield technology platform by purchasing key assets tied to the carinata crop. Carinata is under development as a feedstock for renewable fuels as well as a high-protein, non-GM meal intended for livestock feed. In financial year '20, an independent third-party certifier verified that Nuseed's carinata cropping system and the oil it produces rank best-in-class among agricultural feedstock crops for reducing greenhouse gases. That fact supports meaningful premiums on carinata oil. We signed a multiyear offtake agreement with St. Paul, Europe's biggest oilseed crusher and biodiesel producer, and finished an initial commercial sale and shipment of a crop from Argentina to Europe. Nuseed's proprietary carinata platform features a closed-loop contracting system with growers, carrying the commercial certainty provided by our St. Paul agreement, and with sales confirmed into downstream fuel brands, we have considerably broadened grower contracting for the 2020 crop. Before I turn things back to Greg, a few other remarks. Going forward, I am confident we have passed a significant threshold that puts Nuseed in position for strong earnings and growth in the years ahead. In the current financial year, better seasonal conditions in Australia bode well for an improved canola harvest and plantings.

Brent Zacharias

executive
#32

Additionally, we'll record endpoint royalties tied to robust hybrid canola sales in financial year '20. With further new products set to launch throughout every region, we anticipate gaining share in sunflower and sorghum across North and South America as well as Europe. Financial year '21 should likewise bring a step-up in crop production, commercial activity, and the related sales linked to our omega-3 canola and carinata Value Beyond Yield platforms. Now that initial commercial arrangements have been secured for both Aquaterra and carinata, FY '21 should deliver positive EBITDA contributions from each of these programs. Past FY '21, continuing ramp-up in Aquaterra and carinata oil production will drive cost efficiencies and margin improvement, thanks to both greater scale and better performing seed rise. Along with our exciting Nutriterra omega-3 opportunity in human nutrition and ongoing growth in seeds contribution, I believe we'll see a progressive step change in value revenues and earnings from the Nuseed platform over the next 4 years. I'll now hand it back to Greg.

Gregory Hunt

executive
#33

Thanks. Appreciate it, Brent. So, to wrap things up: 2020 was a really tough year, no question. Even so, we've made solid headway on a number of initiatives that have made the business stronger. And we think that's going to translate into better returns. Our balance sheet is in much better shape, and we've refocused the portfolio on regions where margins are higher and cash flows are stronger. Beyond safety, our top priority for 2021 is lifting returns in our European business. A turnaround there, plus the gains from the wider performance improvement program, can produce a very meaningful boost to earnings in 2021. Our cash generation is getting better. And as Paul laid out, there's room to improve further. Nuseed keeps reaching major milestones. And as Brent just walked us through, that first commercial sale of omega-3 truly signals a move into the next phase of commercialization, and we really do believe this is a very valuable business, and we're excited about what it can deliver in the years ahead. We finished 2020 with positive momentum, and that has carried on into August and September. With that, I'll turn it back to the operator to take your questions.

Operator

operator
#34

<<operator_script>> The initial query will be taken from Mr. Grant Saligari of Crédit Suisse.

Grant Saligari

analyst
#35

If I could, a couple of questions about Europe, please. First, I suppose I would just be interested to hear your view on maintaining competitiveness as a senior phenoxy manufacturer over the longer term. And maybe tied to that, I am just interested in where you believe, or how well you believe, your product portfolio is positioned as the European Green deal keeps developing, because as you yourself acknowledge, you have a very traditional chemistry SKU in Europe. So I would be interested in your views on both of those, please.

Gregory Hunt

executive
#36

Yes. Thanks, Grant. Well, I'll take the first 1, and then Hildo can address the product portfolio and what the potential impacts on farm default might be. So, regarding phenoxies: what we're really discussing is our MCPA and specialty phenoxies business in Wyke. We're a global leader there. And the output from that operation is competitive on a global scale. We've planned to put modest capital in to debottleneck production and bring down our operating costs in FY '21. But we think that operation is sustainable. Hildo, would you like to offer a few comments about the portfolio?

Hildo Brilleman

executive
#37

Yeah. So if we turn to phenoxies MCPA and the products derived from them — sure, this is a chemistry that's been with us for a good while now. As for where these products stand on the regulatory side, they're actually quite secure. And it's also worth pointing out that as other products exit the market, these take on a more prominent role in our farmers' wheat control program, particularly when we consider wheat resistance. So the reason we invest is to keep that competitiveness going, but also to keep growing that business.

Grant Saligari

analyst
#38

Hildo, what other products are being pulled from the market?

Hildo Brilleman

executive
#39

Regarding the herbicide, naturally, you're hearing about the strain on glyphosate. Yet yes, a broad array of products is undergoing the NX1 renewal process. And that stands apart from the European Green deal. What's worth noting here is that fresh opportunities will arise as items exit the market, though naturally, some effects on our business exist too. But that has been planned for, and it has been factored in going forward.

Grant Saligari

analyst
#40

What I'm really trying to get at, I suppose, is this: as the Green Deal keeps evolving—and it appears to be moving in just one direction—do you feel that more product development is needed on your side, or that the mix within your product range has to be altered?

Hildo Brilleman

executive
#41

Yes. That is a good question. But if I consider one of the main products in our development pipeline, it actually combines Century and Surf chemistry with the phenoxy chemistry we have, which produces a new and differentiated mixture. And this is precisely the kind of innovation we are able to do now given this broader product range. And our assessment from a regulatory standpoint is that this product will get registered and can indeed take up more room in the market. So that pertains to the phenoxy range.

Grant Saligari

analyst
#42

Alright, let me slip in 1 more short question if I may. Looking at expenses, I saw that R&D was likely the sole line item that went down. So I wanted to ask whether some timing effect on R&D programs is at play there, or what might explain that decrease, please.

Paul Binfield

executive
#43

Yes, Grant, R&D spending does have a tendency to be rather uneven by nature. Certainly, when it comes to what we do in R&D, it's reasonable to say we're likely more concentrated in that area. And you can probably anticipate a step-up in R&D expenditure carrying through into '21. So after we have been through tough times, with cash having been tight and very carefully managed across the last couple of years, we have absolutely not scaled back our R&D program. What you're seeing there is simply a matter of phasing. So expect a step-up where next year is concerned.

Grant Saligari

analyst
#44

And can you offset that using other cost reductions beyond the $35 million to $40 million? Or should we think of that as only partly covering that $35 million to $40 million as it comes through?

Gregory Hunt

executive
#45

My view is that you ought to treat that as something of a partial offset, since, as I mentioned, our focus is on ensuring we have a solid product pipeline coming through and on continuing to put investment into that area. So compared with the expense level you see for the current year, there will be a step-up. That is going to partially offset the cost improvement program we laid out.

Operator

operator
#46

Alex Karpos of Goldman Sachs has the next question on the phone line.

Alex Karpos

analyst
#47

Let me start with a quick question of my own. Could you give a bit of detail on channel inventories, perhaps looking at it from a group perspective? And then, are there any regions that really stand out as either especially full or especially well positioned going into FY '21?

Gregory Hunt

executive
#48

Yes, Alex. So perhaps the cleanest approach there is for us to move quickly through each region. In North America, as we said at the half, channel inventories were elevated due to carryover from the prior period. At this point, channel inventories in North America — certainly where herbicides are concerned — look more normal. Our information suggests there are likely still somewhat elevated levels of insecticides and fungicides, but for herbicides specifically, a decline, and we'd be in a good position to meet any pickup in herbicide demand. Here in Australia, once again, we've run a very robust sales program across the last 6 months, and that has carried through into August or September. So certainly, looking at the last 2 years, we're much better placed than previously. And I think in Europe — and Hildo may want to add more. I believe he mentioned that we do hold some inventory in Europe given the extremely weak demand in the last quarter. So we'll enter this period carrying more inventory than we'd prefer, but demand in Europe has begun to improve over the last couple of months.

Gregory Hunt

executive
#49

Beyond that, though, I'd say our inventory position is quite strong. Hildo, would you like to add anything about Europe?

Hildo Brilleman

executive
#50

Yeah, I’m with you on that. And it’s true that channel inventories for cereal fungicides and PGRs are running above normal. Still, we’ve got solid visibility into it, and we’ve factored that into how we’re planning going forward.

Alex Karpos

analyst
#51

Thanks. Turning now, I suppose, to the parts hit harder by COVID — namely U.S. turf and ornamental and European horticulture — have you noticed a rebound in those during the last few months, or do they remain fairly depressed?

Gregory Hunt

executive
#52

So I'd say growth in Australia is definitely strong, and there's good momentum in Europe. North America is somewhat more subdued. And in crop, within the crop segments, we're beginning to see some activity. But when it comes to the T&O segment, I'd be cautiously optimistic. Demand there is still a bit — certainly flatter than what you'd typically see at this point in the year.

Alex Karpos

analyst
#53

Understood. And one more brief question, if that's all right. Apologies—please continue.

Hildo Brilleman

executive
#54

And just to add a point on ornamentals in Europe — that market is coming back. It lost 70% at the height of the pandemic. Even so, we're seeing growers return and put in new crops. As a result, the recovery is happening quite quickly.

Alex Karpos

analyst
#55

And one more quick thing, if I can. I appreciate the extra detail you provided on the European earnings bridge—very helpful. But looking ahead to next year, you mentioned a $12 million raw material cost headwind for FY '20. If those raw material costs were to remain at spot, as you laid out with the chart on Slide 22, I believe, would that $12 million fully reverse? Would it reverse only in part? How should we think about the current pricing environment and, I suppose, in more numerical terms?

Gregory Hunt

executive
#56

Hildo, would you like to give that a try?

Hildo Brilleman

executive
#57

Yes. So there are several factors in play here. Naturally, we have some inventory that needs to be worked through. We're seeing significant AI decreases — AI price reductions coming down the line. So we expect that benefit to come through in the back half of the next fiscal year. So I'd say that with the inventories we're holding, not all of those headwinds will reverse, but we'll make solid progress on that in the second half of fiscal year '21. And along with our cost containment efforts, a program to reduce conversion cost, we'll see the benefits of an overall reduction in cost of goods sold in the second half of next year.

Operator

operator
#58

Our next question comes over the phone from Richard Johnson of Jefferies.

Richard Johnson

analyst
#59

Greg, may I begin with the plant shutdowns? I'd like you to walk through the reasoning and strategy behind them once more. I'm asking with that in mind, especially given how long the program runs, and considering what you said about momentum in the business and demand looking better across many of the key areas. And presumably none of that is changing your decision — that's clear — but I'm simply trying to genuinely grasp what the thinking is.

Gregory Hunt

executive
#60

When it comes to the long-dated stuff, it really comes down to registrations. If you shut factories, you have to be sure that the alternative source has a registration. Take Linz, for instance — we supply product from there into Brazil. Under our agreement with Sumitomo, we'll keep supplying product from that factory until registrations for the alternative source are obtained, and we'd expect that to occur within the transition period. And here in Australia, with the insecticides and fungicides operations, again, we'll look to source some of that from China, some from the U.S., and some of that production from Malaysia — which is part of why we're looking to create the Asia Pac region. So all of that takes time.

Richard Johnson

analyst
#61

Understood. So going back to that earlier question about pricing and raw materials in Europe — is there a risk that, as raw materials come down, given the competitive backdrop you're seeing, which presumably won't shift much, that this actually speeds up price declines? And as a result, wipes out any margin improvement you might get otherwise?

Gregory Hunt

executive
#62

Honestly, I'd say capturing the full amount of that margin could prove hard. Still, to be fair, pricing has actually held up fairly decently. And when you look at the Century and Surf portfolio, our sales for this year were likely in the $220 million to $230 million range. So we're aware we aren't where we'd hoped to be. But as raw material prices decline, we'll likely — and since those prices are falling for everyone, not only for Nufarm — I believe we'll grab as much of that upside as we can. It's hard to predict, and expecting us to get 100% is probably unrealistic, though I'd be disappointed if we failed to secure 60% or 70% of that margin.

Richard Johnson

analyst
#63

Thanks, that's very useful. Now just a few quick questions. The first is for Brent. Could you bring us up to date on the current fish oil price and share what you expect for it moving forward?

Brent Zacharias

executive
#64

Yes. Thank you, Richard. In fact, fish oil prices have remained very steady. I think when the COVID pandemic first hit, there was some initial uncertainty about whether Peru would take its full quota. We did see a bit of movement in fish oil prices then, but they went ahead and locked in, I believe, 95% of a very large quota this year. So that's been interesting. Even so, there's actually a fairly substantial amount of fish oil available in the market compared with what people had originally expected. Prices have stayed pretty stable in roughly that $1,900 to $2,000 per ton range for the Peruvian catch. So over the last 3 years we've seen some notable volatility in fish oil prices, but I'd say it shows that even with the COVID impact, fish oil pricing is remaining comparatively high and fairly steady.

Richard Johnson

analyst
#65

Alright. And I really can’t let Paul dodge the questions. So these should just be a couple of simple ones, I’d assume. If I’m not mistaken, you recorded an onerous contract below the line. Maybe you’ve already covered this, and if so, I apologize. Still, I was hoping you might share some specifics about it?

Paul Binfield

executive
#66

Yes, absolutely. That onerous contract provision has to do with supplying 2,4-D from our phenoxy facility to Sumitomo LatAm, following the transitional supply arrangement. It was wrapped into that specific transaction. So basically, what we've observed is that the China price — or what 2,4-D out of China costs — has dropped below the production cost at Linz. As Greg said, several of those products carry registrations that are linked to Nufarm-related manufacturing sites. No alternatives exist, and so at this point we essentially have an onerous contract, in the sense that we'll be supplying Sumitomo beneath our cost of goods.

Richard Johnson

analyst
#67

All right, so from here on there’s simply no margin at all, then?

Paul Binfield

executive
#68

So really, that's a negative margin. But clearly, when the provision gets released, it'll wipe out any loss.

Richard Johnson

analyst
#69

Understood. And could you remind me of the royalty income you previously recorded for Europe to Latin America? I realize that figure isn't particularly large, but I'm simply curious.

Paul Binfield

executive
#70

Off the top of my head, Richard, it came in at roughly the $4 million to $5 million range, around that level. But clearly, once again, that's gone now, and I suppose that's part of what you might call the stranded cost — for want of a better term — that we have to work out of the business after LatAm.

Operator

operator
#71

The next question over the phone comes from John Purtell at Macquarie.

John Purtell

analyst
#72

Paul, my best wishes to you too in your future endeavors. And Paul, just to pick up on that point. Regarding the interest guidance you provided for the year, what are the main factors behind it? I think it's reasonable to say it comes in somewhat above what had been anticipated, considering the de-gearing following the Latin American sale?

Paul Binfield

executive
#73

Yes, absolutely, John. So it's true that a portion of that interest comes from the high-yield bonds, which are clearly denominated in USD. Therefore, if interest rates — if exchange rates stay where they are right now, we'll see some decrease in that as we move forward. I think the other genuine positive, as well, that we've observed — and once again, the numbers we've provided to you are essentially pretty much taken straight from our budget. So the other real advantage we've seen since budgeting times is that average net working capital has improved and come in substantially better during the fourth quarter. So once more, that's clearly a key factor when it comes to net debt. So again, there's a possibility that we might even beat those interest targets we've now set out along those same lines as well.

John Purtell

analyst
#74

On the question of why that figure isn't smaller, Paul — sure. Clearly, debt is considerably lower now. So I'd have expected a larger effect showing up in the interest line.

Paul Binfield

executive
#75

Yes, debt is lower. But I suppose what we kept observing across the year, John, was that working capital stayed rather stubbornly elevated in some regions. Clearly, that flows directly into net debt. And in the most recent quarter, we've witnessed a considerable improvement on that front. As a result, net debt has fallen quite substantially. So my point is that if we're able to keep that favorable trend going, then my expectation would be that the actual interest we can deliver in Q1 comes in under the target we previously set out.

John Purtell

analyst
#76

Alright, and this is a wider question for Greg and Hildo, again somewhat centered on Europe. I mean, we've discussed phenoxies quite a lot. But regarding how fungicide and insecticide look going forward, what's your view? And what competitive pressures exist out there? I mean, are those pressures far more evident for phenoxies and less so when it comes to fungicide and insecticide?

Gregory Hunt

executive
#77

I'd say, John, that pricing pressure in commodity products is definitely still there. The portfolio we acquired is better shielded from that pressure. And as Hildo mentioned earlier, it gives us a way to improve both mix and margins. Hildo, is there anything you'd like to add?

Hildo Brilleman

executive
#78

Right. When your offering is just one AI product, you face competitive pressure from generic entrants as well. In cases where we have differentiated mixtures, that is where more value can be retained. And another point I want to raise is that, with the asset benefit stemming from the Century and Surf portfolio, we hold a real gem, since there are plenty of competitive exits. And acetamiprid has managed to fill part of that gap, and thanks to label and geographical expansion for that product, we keep growing the margin from that insecticide.

John Purtell

analyst
#79

And picking up on that final point. I mean, could you speak in general terms about any new material product registrations that are coming through? Because previously, we've discussed pipeline quite a bit. And then presumably, there will be greater emphasis on that fungicide and insecticide?

Gregory Hunt

executive
#80

Regarding Hildo...

Hildo Brilleman

executive
#81

Greg, was that…

John Purtell

analyst
#82

Yeah. That was just about — if you could give us some kind of color on how many product registrations are coming through, or the extent of them, are they more or less than usual coming through the pipeline?

Gregory Hunt

executive
#83

Hildo, are you there?

Hildo Brilleman

executive
#84

Yes. No. As I mentioned, regarding the Century and Surf portfolio, in areas where we have both capability and a solid opportunity, extending geographically and across labels while also adding more crops is a central element of our product development strategy. This is already materializing in the fiscal year ahead as well as in subsequent years. I'd also like to highlight that through the Surf acquisition, we obtained a very strong range of sulfonylurea herbicide chemistry. We have launched, and are currently in the process of launching, several differentiated mixtures in that space. And we are observing greater uptake along with growing momentum behind these new product introductions. So that's a strong illustration of how we are increasingly unlocking the potential of the Century and Surf portfolio now that these portfolios have been integrated.

Gregory Hunt

executive
#85

John, I'd like to tack on one more point there, if I may. While we are seeing some departure from our portfolio, there are also benefits coming our way as competing products leave the market. For instance, chlorothalonil and epoxiconazole will not be sold in the market next year. Those products, or products that contain those compounds, carry a market value of roughly EUR 400 million. So we'd anticipate that tebuconazole and prochloraz products stand to gain strongly from these exits, and they genuinely serve as workable substitutes for farmers at comparable price points. So we still believe that acquisition, considering what's going on in the market, is disappointing at this point. But as we've noted, I think on many occasions previously, these are quality products. They're recognized brands. They have a role to play in the market. And as we watch some other products drop out, the opportunity for these products becomes simply that much larger.

Operator

operator
#86

The next question over the phone comes from Evan Karatzas at UBS.

Evan Karatzas

analyst
#87

Thanks for laying out that European recovery picture in such detail—it's genuinely useful. Could I shift us over to North America for a moment, and would you speak to how COVID and all of that affected T&O EBITDA there? I'm just hoping to get a feel for what the recovery might look like as we move ahead.

Gregory Hunt

executive
#88

Honestly, I'd estimate roughly $10 million of revenue there, along with $4 million to $5 million in EBITDA.

Evan Karatzas

analyst
#89

All right. Great. And then, apologies, just one final thing regarding North America. That fresh distribution deal that you've secured or been awarded — could you share any additional detail on it? And even for a handful of those from the past 2 years, yes, a bit more detail would be wonderful.

Gregory Hunt

executive
#90

On the sales side, I'd say roughly $30-odd million?

Paul Binfield

executive
#91

That's correct.

Gregory Hunt

executive
#92

On the revenue side, that comes to roughly $30 million.

Evan Karatzas

analyst
#93

Yeah. Great. Okay. And then only one more thing. Moving on to omega-3 for <<inaudible>>. Could you share a little extra color and detail regarding which regions you've secured sales in, or the number of customers that have signed up? Or any kind of -- or the areas you're focusing on at present, Chile or Canada or Norway, I suppose?

Brent Zacharias

executive
#94

Yes, absolutely. Thanks. I believe we've communicated for quite a while that Chile has been our main area of focus, or where we initially launched, and that's where — in those sites, we carried out a great deal of our work. So yes, I can't verify that our very first sales went to a globally leading company that happens to operate locations in Chile. But I'd also describe our position as considerably wider than that. We are in highly advanced talks with several industry participants and receiving substantial backing. So we're being somewhat cautious about the level of detail we share on that at this moment, since it remains a rather sensitive period for us with many conversations underway. But yes, to answer your question, Chile is a genuinely vital first market for us. Yet as we scan other regions, clearly places such as North America — Canada in particular — and Europe, namely Norway and the U.K. over time, are definitely targets for us when we consider the advantages we've managed to show, especially in salmon production.

Operator

operator
#95

And taking the last question in the queue today, we have Anna Guan from Wilsons.

Anna Guan

analyst
#96

A lot of what I wanted to ask has already been covered. Still, I have one last question about cash flow. Paul, could you walk us through how that normalization came together, especially regarding the LatAm sale and that $417 million?

Paul Binfield

executive
#97

Yes. Yes. So basically, it sounds like you located that Note 6, and that just kind of helps carry you from the underlying operating cash flow through to the reported figure. You have to keep in mind that the — we sold the LatAm business at the peak of their working capital cycle? So that significant $400 million cash outflow that you're seeing there essentially is the sale of the LatAm net working capital as at the 31st of March. And if you look down at sort of a couple of lines to the net investing bit, you'll see the cash that we received from Sumitomo wasn't the $1,188 million purchase price. It was something over $100 million higher than that because that's essentially the working capital adjustment that we got Sumitomo to make, reflecting the fact that working capital is at a higher level. Does that help you?

Anna Guan

analyst
#98

Yeah, that's helpful. Let me ask a follow-up, if I may. I was going through Note 12 in the accounts, so the FY '20 working capital is visible there. What kind of drag did that represent compared with the PCP?

Paul Binfield

executive
#99

Regarding net working capital, then...

Anna Guan

analyst
#100

Absolutely.

Paul Binfield

executive
#101

Anna, which area are you referring to exactly?

Anna Guan

analyst
#102

Now, if you turn to page — it's Note 12, on page 74 of the accounts, is that right?

Paul Binfield

executive
#103

Yes. So basically, and specifically, what is your concern? Well, we've laid out there, clearly, the assets that were sold. And you'll notice that the asset working capital at that specific stage of the business cycle sits pretty much at its peak. I'm not certain I follow your question. I'm glad to take it up off-line if you'd like, Anna, and walk you through the detail.

Anna Guan

analyst
#104

No, no, no — now I get what you're saying.

Operator

operator
#105

That brings us to the end of the question portion. I’d like to return the call to the speakers so they can offer their closing remarks. Please go ahead.

Gregory Hunt

executive
#106

Okay, so, well…

Executive

executive
#107

Actually, I believe a few additional questions are still in the queue. Kevin, let's take one or 2 more.

Operator

operator
#108

Belinda Moore of Morgans is the source of the next question we take by phone.

Belinda Moore

analyst
#109

Paul, on page 6 of your accounts, where the guidance for the 30th of September — the new financial year — is provided, may I just verify something? Is the 2-month stub period included in that, making it effectively 14 months' worth? Or does it come to 12 months?

Paul Binfield

executive
#110

No. That's a 12-month figure.

Belinda Moore

analyst
#111

Only 12?

Paul Binfield

executive
#112

That's a 12-month period, Belinda. Right — twelve months, with 1 October as the start date.

Belinda Moore

analyst
#113

Okay. And one more thing — could you confirm what the Greenville facility adds in '21 to the annualized EBITDA impact, please?

Paul Binfield

executive
#114

Are you asking about the real D&A — the effect of depreciation?

Belinda Moore

analyst
#115

Sorry — no, what sort of earnings are you aiming for at that facility? In '21, what kind of uplift do you expect?

Paul Binfield

executive
#116

Yeah, it's tough to give you an exact figure, in a way. The real advantage from Greenville is lower costs. So regarding the business case we submitted to back that investment, the cost savings sit somewhere around USD 3 million to USD 5 million. And we've obviously captured part of that in the present year, since the plant was commissioned in October and began reaching more commercial volumes during the second half. So a share of it will definitely show up in the second half. I believe an additional increment will come through in FY '21.

Belinda Moore

analyst
#117

Okay. And after the South American operations were sold, you mentioned that reducing corporate costs will always be a target — today those were an outflow of a bit less than $57 million. How should we think about that going forward?

Paul Binfield

executive
#118

Right. So, I believe we also included on a slide the anticipated gains from the cost-reduction initiative now in progress. And corporate is squarely in the crosshairs there. Basically, you should anticipate corporate expenses declining by an additional $5 million.

Belinda Moore

analyst
#119

During 2021?

Paul Binfield

executive
#120

That's right.

Belinda Moore

analyst
#121

Okay. And then as a final question, would it be reasonable to say that the 40% working capital target is achievable in '21?

Paul Binfield

executive
#122

Honestly, getting to 40% in '21 is going to be a real challenge. I'd expect us to come in under this year's 46%, though I genuinely believe that reaching 40% is entirely doable in '22.

Operator

operator
#123

Jonathan Snape of Bell Potter is on the line with our next phone question.

Jonathan Snape

analyst
#124

I've got a few more questions about those guidance figures on Page 6 that were put out there, and I appreciate that you already commented on the interest level. But regarding the step-up in depreciation and amortization of roughly $20 million compared with what you've just put out — can you tell me what's driving that?

Paul Binfield

executive
#125

Yes. Look, I believe part of that will involve extra depreciation flowing through from a full year of Greenville. You're also at a point where omega-3 commercialization, clearly, is well along, so we'll begin amortizing that amount. We have a full 12 months of carinata. And of course, once more, carinata commercialization starts up this year. And again, the launch of some new products moving through the pipeline — so the areas we mentioned, the gold product in North America, plus a number of new products coming through in the ANZ business too. So there's really a fair amount of activity when it comes to commercializing the new portfolio coming through, Jonathan. And that's the catalyst driving higher D&A.

Jonathan Snape

analyst
#126

All right. So when I break it down, there's $75 million, $80 million of interest, $220 million of D&A, and then FX. I believe previously you said it runs roughly $1 million a month just to keep that going. So let's call it $10 million. That puts you at roughly $310 million of costs below D&A before tax. I'm just trying to build the bridge here, because if I look at what you just reported for EBITDA this year, and at that chart you did for Europe, you probably had — let's call it — $25 million of seasonal stuff that you should get back if things are normal and you open your door. If I look at the summer crop versus what you would have done 2, 3 years ago, you should have $20 million there. I think you called out a couple of things in the U.S., T&O — I think you mentioned earlier about $5 million — and you get about, I don't know, roughly 1/3 of those savings probably coming through. What I'm trying to figure out is, do you guys actually expect to report a net profit after tax in 2021?

Paul Binfield

executive
#127

Absolutely, that's correct.

Jonathan Snape

analyst
#128

You do. All right. Anything significant, since it operates as a waterfall, reaching that point is rather difficult.

Paul Binfield

executive
#129

Jonathan, in the current environment, I don't think you'd really expect us to be providing guidance out there. And the rules surrounding this are quite tough right now. So that's not something I can really answer.

Operator

operator
#130

Ladies and gentlemen, we have no more questions right now. Today's meeting is now finished. Thank you all for taking part. Everyone may disconnect. Have a wonderful day.

Gregory Hunt

executive
#131

I appreciate that.

Paul Binfield

executive
#132

I appreciate that.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Nufarm Limited transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Nufarm Limited earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Nufarm Limited or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.